Tr1X has won an FDA green light for a clinical trial testing TRX319, a cell therapy designed to restore immune balance, for ...

Kernal has been awarded up to $48M funding to accelerate the development of KR-402, a next-generation in vivo CAR T-cell ...

A 24-parameter spectral flow cytometry panel was developed to monitor immune receptor expression in MS patients, aiding personalized treatment approaches. The panel detects 12 treatment-associated ...

To insert an in-cell picture saved on your device, from Microsoft's gallery, or imported through the web images search, first ...

A new human liver organoid microarray developed by Cincinnati Children’s and Roche recreates immune-driven liver injury in ...

On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy ...

Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...

Naïve B cells exit quiescence and enter a proliferative state upon activation, ultimately differentiating into antibody-secreting or memory B cells. Toll-like receptor (TLR) ligands, such as ...

In experiments with mouse models of breast, pancreatic, and muscle cancers, researchers at Johns Hopkins All Children's Hospital report new evidence that a novel means of boosting the natural immune ...